Share |
News

SeeThruEquity Initiates Coverage on Verisante Technology, Inc.


August 14, 2013 at 5:00 pm

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that SeeThruEquity, an investment research firm, has initiated coverage on the Company.

SeeThruEquity provides research on companies with market capitalizations below $1 billion. The report on Verisante is now available for download at the following address (cut and paste into browser):

http://library.constantcontact.com/download/get/file/1108926845265-22/VRS+Initiation.pdf

About SeeThruEquity, LLC

SeeThruEquity, LLC is an investment research and corporate access firm that produces high quality research reports on smallcap and microcap companies with less than $1 billion in market capitalization. These companies have typically been underserved by the traditional Wall Street analyst establishment. We are unfettered by any ties to investment banking or trading, and distribute our high impact research as an approved firm for consensus estimates on Thomson Reuters, CapitalIQ, FactSet, Zacks and StockTwits, as well as to our own audience of investors from our corporate website.

The investment opinions expressed are solely those of SeeThruEquity. SeeThruEquity has not been compensated for the preparation of its report on the Company by any third party or the Company.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale. 

Verisante Aura™ was awarded Popular Science Magazine’s “Best of What’s New Award” for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013.  Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. 

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. 

Company Contact:

Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: (604) 605-0507
Email: info@verisante.com
Website:  www.verisante.com
Youtube:  www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Forward Looking Statements 

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

 

  Back to top